Barcelona-based Grifols has agreed to acquire the operations of a fellow maker of blood plasma products, Talecris Biotherapeutics in North Carolina, for $4 billion in cash, stock and debt. The acquisition will expand Grifols’ presence in the United States, giving the company control of about one-third of the market.
Both companies collect blood samples from healthy donors at centers across the country, from which blood plasma is used to create therapies for blood-related disorders. Plasma is the liquid component of blood that carries blood cells.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
